Work

Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)

Year: 2021

Type: article

Source: Annals of Surgical Oncology

DOI: 10.1245/s10434-021-09897-w

Authors: Anna Weiss, Jordan Campbell, Karla V. Ballman, William M. Sikov, Lisa A. Carey, E. Shelley Hwang, Matthew M. Poppe, Ann H. Partridge, David W. Ollila, Mehra Golshan

Institutions: Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, Cornell University, Weill Cornell Medicine, Brown University, Women & Infants Hospital of Rhode Island, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Duke University, Huntsman Cancer Institute, Yale Cancer Center, Yale University

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Breast Cancer Research Foundation, Eli Lilly and Company, AstraZeneca, National Institutes of Health, Genentech, National Cancer Institute

Awards: G1309944872, G1327407074, Yale Cancer Center NCTN LAPS, G4017138494, G4182407434, G4185274752, NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care, UNC Lead Academic Participating Site, G6984334316, G8225661566, Alliance for Clinical Trials in Oncology Operations Center, G9000295587, G9000309961

OpenAlex ID: W3145883540

FWCI: 2.14

Cites: 54

Cited by: 43

Related to: 10